Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | KIF11 | P52732 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.48 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30871637 | 0.88 | MEN1 (0.50) | MEN1KMT2ATDP1KIF11MAOA | |
| SCHEMBL29679194 | 0.86 | KIF11 (0.65) | MEN1KMT2ATDP1KIF11CHRM2 | |
| SCHEMBL12264131 | 0.83 | KIF11 (0.74) | MEN1KMT2ATDP1KIF11KCNN4 | |
| SCHEMBL3435476 | 0.81 | KCNN4 (0.58) | MEN1KMT2ATDP1KIF11MAOA | |
| SCHEMBL5764 | 0.81 | MEN1 (1.00) | MEN1KMT2ATDP1MAOACHRM2 | |
| SCHEMBL4913828 | 0.79 | MEN1 (0.94) | MEN1KMT2ATDP1MAOACHRM2 | |
| SCHEMBL4922899 | 0.79 | MEN1 (0.94) | MEN1KMT2ATDP1MAOACHRM2 | |
| SCHEMBL5040570 | 0.79 | MEN1 (0.94) | MEN1KMT2ATDP1MAOACHRM2 | |
| Water SCHEMBL4230715 | 0.79 | MEN1 (0.94) | MEN1KMT2ATDP1MAOACHRM2 | |
| Ammonia Solution, Strong SCHEMBL6678345 | 0.79 | MEN1 (0.94) | MEN1KMT2ATDP1MAOACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117222646-A | KRAS G12C inhibitors and uses thereof | 苏州赞荣医药科技有限公司 | 2023-12-12 | — | — | CN | disclosed |
| EP-4182308-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-05-24 | — | — | EP | disclosed |
| CN-116096719-A | Pyridazinylamino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2023-05-09 | — | — | CN | disclosed |
| WO-2023040989-A1 | KRAS G12C INHIBITORS AND USES THEREOF | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2023-03-23 | — | — | WO | disclosed |
| US-10017509-B2 | Macrocylic pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-10 | — | — | US | disclosed |
| US-20180127423-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE DEUTSCHLAND (DE) | 2018-05-10 | — | — | US | disclosed |
| EP-3126364-B1 | MACROCYLIC PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-07 | — | — | EP | disclosed |
| US-9701679-B2 | Modulators of 5-HT receptors and methods of use thereof | Abb Vie Deutschland GmbH & Co. KG (DE) | 2017-07-11 | — | — | US | disclosed |
| EP-3150607-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | AbbVie Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2560973-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-2421870-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2016-03-09 | — | — | EP | disclosed |
| EP-2522671-B1 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015150555-A1 | MACROCYLIC PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | WO | disclosed |
| US-20150175611-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-25 | — | — | US | disclosed |
| US-8846663-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130310368-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC. | 2013-11-21 | — | — | US | disclosed |
| US-8546377-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8518933-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2522671-A2 | Modulators of 5-HT receptors and methods of use thereof | Abbott Laboratories (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20100273767-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310368-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | MEN1 2826/4885KMT2A 2053/4885TDP1 1761/4885 |
| US-20180127423-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | MEN1 2826/4885KMT2A 2053/4885TDP1 1761/4885 |
| US-10017509-B2 | Macrocylic pyrimidine derivatives | EEF2K, VPS26B, VPS28 | MEN1 4634/4885KMT2A 3569/4885TDP1 1399/4885 |
| US-20100273767-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | MEN1 2826/4885KMT2A 2053/4885TDP1 1761/4885 |
| US-20150175611-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | MEN1 2826/4885KMT2A 2053/4885TDP1 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.